Harada Kaoru, Heaton Henry, Chen Jason, Vazquez Marietta, Meyer Jaimie
Department of Internal Medicine, Yale-New Haven Hospital, New Haven, Connecticut, USA.
Department of Dermatology, Yale-New Haven Hospital, New Haven, Connecticut, USA.
BMJ Case Rep. 2017 Aug 22;2017:bcr-2017-221166. doi: 10.1136/bcr-2017-221166.
A 64-year-old immunocompetent man developed a widespread pruritic and vesicular rash 2 weeks after receiving the zoster vaccine (Zostavax). He had fever, bandaemia with normal total white blood cell count and mild transaminitis. PCR testing of serum and skin was positive for varicella zoster virus (VZV), while serum VZV IgG was negative. The analysis of single nucleotide polymorphism by PCR and sequencing from the skin swab was consistent with the vaccine strain. The patient received 1 week of intravenous acyclovir and was discharged after all lesions had crusted. He continues to do well on follow-up with no significant complications.
一名64岁免疫功能正常的男性在接种带状疱疹疫苗（Zostavax）2周后出现广泛的瘙痒性水疱皮疹。他有发热、白细胞总数正常的带状病毒血症和轻度转氨酶升高。血清和皮肤的PCR检测显示水痘带状疱疹病毒（VZV）呈阳性，而血清VZV IgG呈阴性。通过PCR和皮肤拭子测序对单核苷酸多态性进行分析，结果与疫苗株一致。患者接受了1周的静脉注射阿昔洛韦治疗，所有皮损结痂后出院。随访期间他情况良好，无明显并发症。
